Sarah Hein, co-founder and CEO of March Biosciences, joins the Houston Innovators Podcast to discuss how the company will use its series A funding. Photo via march.bio

When cancer originates in a patient, their body fights as hard as it can against the disease, but sometimes, the cancer wins the battle. However, one Houston cell therapy startup is working on an artillery of therapeutics to help arm patients' bodies to win the war.

Founded in 2022, March Biosciences is a cell therapy company born in part out of the Texas Medical Center's Accelerator for Cancer Therapeutics, where Sarah Hein served as inaugural entrepreneur in residence. In that role, she met her co-founders Max Mamonkin and Malcolm Brenner.

Now, leading the startup as CEO, Hein tells the Houston Innovators Podcast that with March's lead product, MB-105, an autologous CD5 CAR T cell therapy, the name of the game is to zero in on advancing this particular treatment to its phase II trial next year.

"Targeted therapies are targeted. Our target is expressed on these T-cell cancers, and there are a couple other cancers, like Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia," Hein says on the show. "Unfortunately, I don't think there's ever going to be a magic bullet that is going to hit a huge swath of these cancers. We're going to continue to chip away at these cancers by creating really elegantly engineered therapies against these different kinds of tumors.

"March, in general, is committed to this idea that we're going to continue to work on difficult tumors and different targets with our uniquely engineered targeting strategy against these diseases. As we expand into the next year, you'll see us speak on this a little more on how we're going to continue to work on new diseases that havent been addressed previously," she continues.

Hein explains how March Biosciences — named in part as a nod to one of Houston's best months weather wise — has benefitted from the support of the local life science community. Last year, March announced its partnership with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. Hein says over the past year, they've moved into CTMC and that's allowed them to accelerate their progress as a company.

"Houston has a unique sophistication in cell therapy. Where we've had biotech spinout, cell therapy has been one of our more successful verticals," she says. "We've had resources and knowledge here that were uniquely available for our drug category."

Earlier this month, March Biosciences announced an oversubscribed $28.4 million series A led by Mission BioCapital and 4BIO Capital and bringing the company's total funding secured to more than $51 million, including its prestigious CPRIT grant. Hein says this funding will go toward further developing March's therapeutics and team as it gears up for its phase II trial next year.

Ultimately, Hein explains on the show how passionate she is and her team is on continuing to develop treatments to fight cancer with their targeted approach.

"I never have to explain to people why we would go out and fight cancer. I think it's a self-evident hypothesis," she says. "But what I personally find is exciting in cancer therapies in general are these immune therapies, where you using the body's own immune system to seek out and destroy the cancer cells.

"What's really exciting about that is these are the same immune cells that fight cancer or pre-cancers for most of your life and usually what happens is the cancers figure out a way to mass themselves. With modern approaches, we can boost the immune system."

The Texas Medical Center's ACT program is making sure the most-promising cancer research makes it to its life-saving commercialization stage. Photo via tmc.edu

Houston program buoys promising cancer research with live-saving innovation

act-ing now

How do you bring promising cancer research to the masses? TMC Innovation's Accelerator for Cancer Therapeutics was established with that question in mind.

Funded by a $5 million grant from CPRIT, or the Cancer Prevention and Research Institute of Texas, in 2019 and in collaboration with the Gulf Coast Consortia and the University of Texas Medical Branch, the first cohort began their intensive work in 2021. The deadline to join the next cohort is October 13.

Since its inception, ACT has seen the forming of 19 companies — two of which have been awarded CPRIT seed grants, along with four in contention for one this year — as well as $92 million in dilutive funding and $10 million in non-dilutive funding.

“We’ve recruited investigators and companies from the breadth and width of the state of Texas, so all the way from Lubbock to Galveston from Dallas to the Rio Grande Valley,” Ahmed AlRawi, program manager, tells InnovationMap. “We've had an amazing set of investigators who have gone through the program — 56 teams to be precise.”

AlRawi says that the first pillar of the program is education. To that end, the cohort works with entrepreneurs in residence like Michael Torres. Best known as the co-founder of ReCode Therapeutics, Torres says that one of his greatest passions lies in translating science into medicines. ReCode is a genetic medicines company that is currently clinical-stage. It’s raised more than $300 million in the last two years, certainly something to which scientist-entrepreneurs earlier in their careers would aspire.

A longtime resident of Dallas, Torres moved his family to Houston last year, calling it “the place to be for cancer startups in Texas.”

Initially, says Torres, Houston wasn’t on his radar. But thanks to a call from ACT external advisor Dan Hargrove, Torres realized that the city might be a fit for him and his goals.

“I wanted to find a project that I could help support, sort of take my experience as a cofounder and help guide the next great startup within the ecosystem,” he says.

Torres and AlRawi agree that the biggest successes to come out of ACT so far include March Biosciences, a company from the first cohort, which is focused on developing CAR-T cell strategies to help combat hematological cancers; CPRIT fundee, OmniNano Pharmaceuticals, which uses patented nanotechnology to co-deliver a pair of therapeutical agents to solid tumors; and the latest, CrossBridge Bio.

Part of the most recent cohort, Torres has joined Drs. Kyoji Tsuchikama and Zhiqiang An as the last company’s CEO. To that end, he’s partnered with the world-class researchers out of UT Health Houston to build a next-generation antibody drug conjugate company that he believes will produce “better and safer and more effective drugs than what's currently on the market today.”

All the more reason that Torres he’s glad to have moved to Houston at what he calls “a really exciting time.” He’s thankful for the Texas Medical Center and the relationships it fosters. “We're all sort of aligning on creating a sustainable biotech ecosystem,” he says. And the next big cancer fighting company may well emerge from ACT.

7 Hills Pharma, an innovative immunotherapy company, was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Houston immunotherapy company to use $13.5M grant to further develop cancer treatments

future of pharma

Between Bangalore and Chennai in the Indian state of Andhra Pradesh, you’ll find the town of Tirupati. It’s home to seven peaks that host a Hindu temple complex devoted to a form of Vishnu, Venkateshvara. It is also the region from which Upendra Marathi originally hails. It’s where his father, and many other family members, attended medical school.

“My father’s first job was to take care of the pilgrims,” recalls Marathi.

It's only natural that his groundbreaking Houston company would be named 7 Hills Pharma.

“That sort of selflessness and giving back, I wanted to embody it in the name of the company,” Marathi says.

Now, 7 Hills Pharma is announcing that last month, it was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). That’s on top of more than $13 million in NIH grants, making the company the second largest recipient of SBIR/STTR grants in Texas.

Launched in 2016, 7 Hills Pharma is working to develop drugs that can overcome the all-too-common problem of immunotherapy resistance. Thanks to the Nobel Prize-winning work of Jim Allison in the realm of immuno-oncology, the field was “very hot” at the time, says Marathi, particularly in Houston.

So what has 7 Hills developed? Oral small molecules that activate integrins — the receptors that allow cells to bind to one another — allowing for the cell-to-cell interactions that create a successful immune response to immune checkpoint inhibitors such as Yervoy. In other words, they have created capsules that increase the effectiveness of drugs that allow the body’s own immune response to fight cancers.

But that’s not all. Tests have shown that the same discovery, called alintegimod, can also augment the effectiveness of vaccines. The pill, which co-founder and co-inventor Peter Vanderslice calls “a beautiful way to amplify the vaccines,” can potentially be applied to anything from influenza to coronavirus.

Their greatest challenge, says Vanderslice, is the very fact that the technology is so novel.

“Most large pharmas are very risk averse,” he explains. “They only want to do ‘me-too’ kinds of drugs.”

7 Hills Pharma is the third company Marathi, both a PhD and an MBA, has helped to found based on technology he co-invented. Vanderslice is director of the molecular cardiology research laboratories at The Texas Heart Institute.

“It’s very much a homegrown company,” Marathi says.

And a small one, at least for now. Working out of JLabs@TMC, the full-time team is currently just Marathi and Siddhartha De, the senior director of development. Marathi convinced De to transplant himself and his family from India for the purpose of assisting 7 Hills with preparing its drugs for clinical readiness.

The CPRIT funds will allow 7 Hills Pharma to hire several long-time team members full-time and with benefits.

“The bringing of talent and bringing of technology to TMC and what was born at Texas Heart Institute is rather remarkable,” says Rob Bent, the company’s director of operations.

The next step for 7 Hills Pharma is a Phase Ib/IIa clinical trial in patients with treatment-resistant solid tumors. And the team just finalized the deck that will help raise another $10 million to $250 million in the company’s series A. And hopefully sooner rather than later, a new set of medical pilgrims will be thanking 7 Hill Pharma for its care.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

10+ can't-miss Houston business and innovation events for November

WHERE TO BE

From networking meetups to pitch competitions, November is filled with opportunities for Houston innovators. Here's a roundup of events you won't want to miss out on so mark your calendars and register accordingly.

Note: This post might be updated to add more events.

Featured event: November 14 — Houston Innovation Awards

Celebrate Houston innovation at InnovationMap's 2024 Houston Innovation Awards on November 14 at TMC Helix Park. Click here to read about the finalists. Secure your tickets below.


November 4 - 5 — In-Space Physical AI Workshop

The Rice University Office of Innovation, in partnership with NASA, Purdue University and the Ion District, will host the In-Space Physical AI Workshop. The event will bring together industry leaders, startups, government agencies and researchers to explore the cutting edge of AI in space exploration. Workshop sessions will cover a range of topics in physical AI ⎯ robots or systems that apply AI to autonomously sense, interact with and adapt to their environment using complex computational, sensory and motor abilities to perform challenging real-world tasks.

This event begins Monday, November 4, from 8 am to 8:30 pm at the Ion. Click here to register.

November 6 — Waste to Work: Transforming Waste into Valuable Resources

This event will delve into innovative strategies and technologies that transform waste materials into valuable resources, driving sustainability and economic growth. Topics will include innovative technologies in waste conversion, policy and regulation, economic opportunities in waste management, success stories from around the world, and trends and predictions.

This event is Wednesday, November 6, from 3 to 6 pm at the Cooley University Life Center at UTHealth Houston. Click here to register.

November 7 — Bots & Brews

This event is the fall meetup for the H-town robotics, drones, geospatial, data & AI crowd, hosted by the Energy Drone & Robotics Coalition. Leaders from energy/engineering asset owner/operators, service companies, tech solution providers, startups & investors in the energy and industrial robotics/drone/data & AI community come together to catch up and talk about real-world solutions, projects and deployments.

The event is Thursday, November 7, from 5:30 to 7:45 at The Cannon West. Click here to register.

November 8 — Tech Fest Live

The UH Technology Bridge will be buzzing with students, industry leaders, innovators, and tech enthusiasts as they come together to celebrate the future of technology and innovation. There will be exciting panel discussions, interactive exhibits, and networking opportunities in the fields of digital media, energy, AI and entrepreneurship.

This event is Friday, November 8, from 8 am to 4 pm at UH Technology Bridge. Click here to register.

November 12 — The New Majority Summit

1863 Ventures, a D.C.-based accelerator and venture capital firm, is focused on advancing New Majority entrepreneurs—those historically marginalized or underrepresented—towards greater wealth and success. This immersive program centers on the essential skills and insights needed to transition into becoming an effective CEO.

Throughout the event, registrants will delve into key topics, including the entrepreneurial mindset, understanding one's customer base, establishing scalable processes, financial management strategies, and effective fundraising techniques. Prepare to be inspired and empowered after hearing from 1863 CEO Melissa Bradley, founder & CEO of LAMIK Beauty Kim Roxie, co-founder of Donna's Recipe Gina Woods and more.

This event is Tuesday, November 12, from 8:30 am to 5 pm at the Ensemble Theatre. Click here to register.

November 12 — Software Day at the Ion: Blockchain 2.0: Innovating Across Industries

Software Day is a monthly series driving the support, inspiration, and connections needed to help startups on their path to rapid, sustainable growth. Each month, software day will include office hours (by application), a keynote session, and networking. This software day is moderated by Samantha Lewis, partner at Mercury. Panelists include the former CEO of BBVA Compass, Manolo Sanchez and Ian Epstein, co-CEO ProfitR, global head of capital markets and distribution at republic.

This event is Tuesday, November 12, from 3:30 to 7 pm at the Ion. Click here to register.

November 13 — Envision 2024

Learn how companies in the ecosystem of the largest medical center in the world are addressing challenges head-on, meet some of our entrepreneurs, and network. This event is presented in partnership with Innovate UK and BioInnovation Institute.

This event is Wednesday, November 13, from 1 to 5 pm at TMC Innovation Factory. Click here to register.

November 14 — State of the Texas Medical Center

The Greater Houston Partnership's State of the Texas Medical Center returns. William F. McKeon, President and CEO of the Texas Medical Center, will deliver an annual address, discussing the tremendous progress in discovery and life sciences at the world's largest medical center. New to this year's State of the Texas Medical Center, is a dynamic pitch competition, the TMC Innovation Pitch Tank.

This event is Thursday, November 14, from 11 am to 1:30 pm at Hilton Americas. Click here to register.

November 15 — 2024 ERG Symposium

This event, hosted by Houston Methodist, will include a keynote from Shona Pinnock, VP of DEI for Peloton as well as insights from other local organizations such as HESS, Houston Methodist, TDECU, Greystone and more. These experts will share how ERGS are impacting business goals, enhancing company culture and employee engagement and will provide valuable insights and actionable takeaways to help organizations maximize the effectiveness of ERGs.

This event is Friday, November 15, from 9 am to 1 pm at The Westin Houston Medical Center. Click here to register.

November 19 — A Texas Talk: Reflecting on the Past, Envisioning the Future

Center for Houston’s Future’s signature fall event, Dinner and Conversation presented by Harvey-Cleary, will feature an exciting conversation between two important Texas voices. Stephen Harrigan, the award-winning author of 12 fiction and non-fiction books, will appear in conversation with Sonal Shah, CEO of the Texas Tribune, who has a long record of social impact work across multiple sectors.

This event is Tuesday, November 19, from 6 to 9 pm at the River Oaks Country Club. Click here to register.

November 21 — Visionary Voices: A Fireside Chat with Dan Ammann, President of ExxonMobil Low Carbon Solutions

In this fireside chat, Dan Ammann, president of ExxonMobil Low Carbon Solutions, will discuss ExxonMobil’s plans in advancing a thoughtful energy transition by delivering the critical energy and products the world needs and reducing their own and others’ greenhouse gas emissions. He’ll talk about Low Carbon Solutions’ transformative projects and investments aimed at bringing lower-emission technologies like hydrogen, lithium, and carbon capture and storage to market, making them accessible to carbon-intensive industries worldwide.

This event is Thursday, November 21, from 8 to 10 am at the Ion. Click here to register.

Overheard: Houston's top energy transition founders explain their biggest challenges

Houston Innovation Awards

From finding funding to navigating the pace of traditional oil and gas company tech adoption, energy transition companies face their fair share of challenges.

This year's Houston Innovation Awards finalists in the Energy Transition category explained what their biggest challenge has been and how they've overcome it. See what they said below, and make sure to secure your tickets to the Nov. 14 event to see which of these finalists win the award.

"The evolving nature of the energy industry presents opportunities to solve some of our industry's greatest challenges. At Amperon we help optimize grid reliability and stability with the power of AI demand forecasting."

Sean Kelly, CEO of Amperon, an AI platform powering the smart grid of the future

"The biggest challenge in leading an energy transition-focused startup has been balancing the urgency for sustainable solutions with the slow pace of change in traditional industries like oil and gas. Many companies are cautious about adopting new technologies, especially when it comes to integrating sustainability initiatives. We overcame this by positioning our solutions not just as environmentally friendly, but as tools that improve safety, efficiency, and cost savings. By aligning our value proposition with their operational goals and demonstrating real, measurable benefits, we were able to gain traction and drive adoption in industries that are traditionally resistant to change."

— Dianna Liu, CEO of ARIXTechnologies, an integrated robotics and data analytics company that delivers inspection services through its robotics platforms

"Scaling up production of hard tech is a major challenge. Thankfully, we recruited top-notch talent with experience in technology scale-up and chemical processes. In addition, we've begun building partnerships with some of the world's largest chemical manufacturers in our space who are excited to be a part of our journey and could rapidly accelerate our go to market strategy. We have significant demand for our product as early as 2025, so partnering with these companies to scale-up will bring our technology to market years ahead of doing it alone."

— Matthew Dawson, CEO of Elementium Materials, a battery technology with liquid electrolyte solutions

"Our pyrolysis reactor is a proprietary design that was developed during Covid. We ran simulations to prove that it works, but it was not easy to test it in a pilot facility, let alone scaling it up. We managed ... to run our pilot plant studies, while working with them remotely. We proved that our reactor worked and produced high quality products. Later, we built our own pilot plant R&D facility to continue running tests and optimizing the process. Then, there was the challenge of scaling it up to commercial size. ... We put together a task force of four different companies to come together to design and build this complex reactor in record time."

— Vibhu Sharma, CEO of InnoVentRenewables, a startup with proprietary continuous pyrolysis technology that converts waste tires, plastics, and biomass into valuable fuels and chemicals

"Energy storage and geothermal power generation are capital-intensive infrastructure projects, requiring investors with a deep commitment and the patience in terms of years to allow the technology to be developed and proven in the field. One challenge is finding that niche of investors with the vision to join our journey. We have succeeded in raising our $30 million series A with these types of investors, whom we’re confident will continue the journey as we scale."

— Cindy Taff, CEO of SageGeosystems, an energy company focused on developing and deploying advanced geothermal technologies to provide reliable power and sustainable energy storage solutions regardless of geography

"The biggest challenge we've faced has been to bring together massive independent power producers on one side who are investing hundreds of millions of dollars into grid infrastructure with multi- national tech giants on the other that don't have experience working much with energy storage. As a startup with only four employees, gaining credibility with these players was critical. We overcame this hurdle by becoming the preeminent thought leader on storage emissions, through publishing white papers, discussing the issues on podcasts, and (more)."

— Emma Konet, CTO of TierraClimate, a software provider that helps grid-scale batteries reduce carbon emissions

------

This article originally ran on EnergyCapital.